ANGPTL3 and hyperlipidemia: A consistent and intriguing observation from our studies was, regardless of the degree of hyperlipidemia or effects on steady state measurements of plasma HDL, mice administered the Angptl3 ASO displayed a reduction in the plasma accumulation and an increase in the fecal excretion of radiolabeled cholesterol, suggesting an increase in RCT.